RedShift BioAnalytics has launched Aurora, the company’s latest system using MMS technology. Aurora is designed to provide ultra-sensitive, ultra-precise measurements of the structure of biomolecules through a new technology called Microfluidic Modulation Spectroscopy (MMS), more rapidly, with less sample volume, and with improved software and analytics features. According to the compmay, Aurora delivers a 10-fold decrease in sample volume at a lower price point than the first generation MMS instruments.
 
MMS aims to overcome many of the limitations of existing technologies in a typical biophysical characterization toolkit with ultra-sensitive and highly reproducible structural measurements of proteins and other biomolecules. Users can compare higher-order structure and similarity profiles for confidence in structural similarity and activity to inform discovery, screening, formulation, and quality control in biopharmaceutical drug development. It can be used for a wide range of biomolecules from mAb-based biotherapeutics to robust measurements of proteins, enzymes, peptides, ADCs, AAVs, and mRNA.
 
“We are thrilled to build on the foundation of our first-generation platform with the introduction of Aurora today, which is literally an order of magnitude improvement and will dramatically expand the market for MMS,” said Julien Bradley, CEO at RedShiftBio. “While our previous instruments generated significant enthusiasm from researchers for their sensitivity, precision, and ease of measurements, the sample volume required coupled with the instrument’s cost and complexity were significant limitations. Today I am proud to say that with Aurora, we have put those limitations behind us.”